Press Releases

Neurology Clinical Trials Market to Expand at a CAGR of 7.5 % from 2021 to 2030

Neurology Clinical Trials Market size was valued at USD 6.8 Billion in 2020 and is projected to reach USD 12.5 Billion by 2030, growing at a CAGR of 7.5% from 2021 to 2030.

Download Exclusive Sample of Report@ https://www.visionresearchreports.com/report/sample/38683

Growth Factors

 This is largely attributed to increasing neurological diseases, such as dementia, stroke, and peripheral neuropathy, and growing R&D investments towards neurological research. However, Covid-19 is an unprecedented event that has impacted practically every part of businesses throughout the world while the pharma industry is being tapped to help bring out an effective treatment against the pandemic at the earliest. Trial enrolment, data collecting, and data analysis were all disrupted, causing delays in ongoing clinical trials. As of April 15, 2020, a total of 81 trials with a specific neurological indication had been recognized as being impacted by the pandemic.

Report Coverage

Report Scope Details
Market Size USD 12.5 billion by 2030
Growth Rate CAGR of 7.5% From 2021 to 2030
Base Year 2021
Forecast Period 2021 to 2030
Segments Covered Phase, Study Design, Indication
Regional Scope North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Companies Mentioned IQVIA; Novartis; Covance; Medpace; Charles River Laboratories; SyneousHealth; Icon Plc; GlaxoSmithKline; Aurora healthcare; Biogen

By Phase Analysis

The phase II clinical trials segment accounted the market for neurology clinical trials and held the highest revenue share of 36.7% in 2020. This is largely due to the fact that neurological disorders are extremely rare and there is no specific treatment available. Phase II and phase III trials account for the vast majority of trials. From 1999 to 2020, a total of 8,205 CNS trials were conducted, with 609 trials being conducted in 2020.

The phase III is anticipated to register the fastest growth throughout the forecast period. This growth may be attributed to the fact that phase III clinical trials are the costliest and involve a large number of participants. Phase III also requires a larger number of patients and, in many cases, a longer treatment term.

By Indication Analysis

The Huntington’s disease segment is anticipated to register the largest growth rate of 7.0% throughout the forecast period. This is largely attributed to increasing R&D investment and the high prevalence of the disease all around the globe.

Egypt, the Arab world’s most populated country, has the highest prevalence of Huntington’s disease, the country of 100 million people is overlooked when it comes to Huntington’s disease research. According to a new report, Huntington’s disease affects 2.7 per 100,000 people around the world and 10 per 100,000 in Europe.

By Study Design Analysis

Based on study design, the interventional segment led the market for neurology clinical trials and dominated for the largest revenue share of 82.2% in 2020. It is one of the most prevalent methods for conducting a clinical experiment.

The observational segment is anticipated to witness substantial growth over the forecast period. In a variety of situations, such as post-marketing safety evaluations of drugs or when clinical trials are not feasible, observational studies are routinely used to evaluate treatment effects.

By Regional Analysis

 North America dominated the neurology clinical trials market and lead for the largest revenue share of 46.8% in 2020. The rising prevalence of neurological disorders and the presence of a large number of players in clinical trials is driving the market for neurology clinical trials in the region.

In Middle East and Africa, the market for neurology clinical trials is expected to register the fastest CAGR of 9.2% throughout the forecast period. The Sub-Saharan Africa region is afflicted by neurological, psychiatric, developmental, and substance use disorders that are caused by or aggravated by a lack of adequate nutrition and infectious disease, regardless of the fact that disorders connected to increasing longevity, such as stroke, are on the rise.

Key Players

  • Novartis
  • Covance
  • Medpace
  • Charles River Laboratories
  • Syneous Health
  • Icon Plc
  • GlaxoSmithKline
  • Aurora healthcare
  • Biogen
  • IQVIA

Market Segmentation

  • Phase
    • Phase I
    • Phase II
    • Phase III
    • Phase IV
  • Study Design
    • Interventional
    • Observational
    • Expanded Access
  • Indication
    • Epilepsy
    • Parkinson’s Disease (PD)
    • Huntington’s Disease
    • Stroke
    • Traumatic Brain Injury (TBI)
    • Amyotrophic Lateral Sclerosis (ALS)
    • Muscle regeneration
    • Others
  • Regional
    • North America
      • U.S
      • Canada
    • Europe
      • U.K.
      • Germany
      • France
      • Italy
      • Spain
    • Asia Pacific
      • Japan
      • China
      • India
      • Australia
      • South Korea
    • Latin America
      • Brazil
      • Mexico
      • Argentina
      • Colombia
    • Middle East & Africa
      • South Africa
      • Saudi Arabia
      • UAE

Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/38683

Reasons to Purchase this Report:

– Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
– Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
– Market value USD Million and volume Units Million data for each segment and sub-segment
– Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
– Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players

Table of Contents

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Neurology Clinical Trials Market, By Phase

7.1.  Neurology Clinical Trials Market, by Phase, 2021-2030

7.1.1.    Phase I

7.1.1.1.        Market Revenue and Forecast (2017-2030)

7.1.2.    Phase II

7.1.2.1.        Market Revenue and Forecast (2017-2030)

7.1.3.    Phase III

7.1.3.1.        Market Revenue and Forecast (2017-2030)

7.1.4.    Phase IV

7.1.4.1.        Market Revenue and Forecast (2017-2030)

Chapter 8.  Global Neurology Clinical Trials Market, By Study Design

8.1.  Neurology Clinical Trials Market, by Study Design, 2021-2030

8.1.1.    Interventional

8.1.1.1.        Market Revenue and Forecast (2017-2030)

8.1.2.    Observational

8.1.2.1.        Market Revenue and Forecast (2017-2030)

8.1.3.    Expanded Access

8.1.3.1.        Market Revenue and Forecast (2017-2030)

Chapter 9.  Global Neurology Clinical Trials Market, By Indication

9.1.  Neurology Clinical Trials Market, by Indication, 2021-2030

9.1.1.    Epilepsy

9.1.1.1.        Market Revenue and Forecast (2017-2030)

9.1.2.    Parkinson’s Disease (PD)

9.1.2.1.        Market Revenue and Forecast (2017-2030)

9.1.3.    Huntington’s Disease

9.1.3.1.        Market Revenue and Forecast (2017-2030)

9.1.4.    Stroke

9.1.4.1.        Market Revenue and Forecast (2017-2030)

9.1.5.    Traumatic Brain Injury (TBI)

9.1.5.1.        Market Revenue and Forecast (2017-2030)

9.1.6.    Amyotrophic Lateral Sclerosis (ALS)

9.1.6.1.        Market Revenue and Forecast (2017-2030)

9.1.7.    Muscle regeneration

9.1.7.1.        Market Revenue and Forecast (2017-2030)

9.1.8.    Others

9.1.8.1.        Market Revenue and Forecast (2017-2030)

Chapter 10.      Global Neurology Clinical Trials Market, Regional Estimates and Trend Forecast

10.1.        North America

10.1.1.  Market Revenue and Forecast, by Phase (2017-2030)

10.1.2.  Market Revenue and Forecast, by Study Design (2017-2030)

10.1.3.  Market Revenue and Forecast, by Indication (2017-2030)

10.1.4.  U.S.

10.1.4.1.      Market Revenue and Forecast, by Phase (2017-2030)

10.1.4.2.      Market Revenue and Forecast, by Study Design (2017-2030)

10.1.4.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.1.5.  Rest of North America

10.1.5.1.      Market Revenue and Forecast, by Phase (2017-2030)

10.1.5.2.      Market Revenue and Forecast, by Study Design (2017-2030)

10.1.5.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.2.        Europe

10.2.1.  Market Revenue and Forecast, by Phase (2017-2030)

10.2.2.  Market Revenue and Forecast, by Study Design (2017-2030)

10.2.3.  Market Revenue and Forecast, by Indication (2017-2030)

10.2.4.  UK

10.2.4.1.      Market Revenue and Forecast, by Phase (2017-2030)

10.2.4.2.      Market Revenue and Forecast, by Study Design (2017-2030)

10.2.4.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.2.5.  Germany

10.2.5.1.      Market Revenue and Forecast, by Phase (2017-2030)

10.2.5.2.      Market Revenue and Forecast, by Study Design (2017-2030)

10.2.5.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.2.6.  France

10.2.6.1.      Market Revenue and Forecast, by Phase (2017-2030)

10.2.6.2.      Market Revenue and Forecast, by Study Design (2017-2030)

10.2.6.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.2.7.  Rest of Europe

10.2.7.1.      Market Revenue and Forecast, by Phase (2017-2030)

10.2.7.2.      Market Revenue and Forecast, by Study Design (2017-2030)

10.2.7.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.3.        APAC

10.3.1.  Market Revenue and Forecast, by Phase (2017-2030)

10.3.2.  Market Revenue and Forecast, by Study Design (2017-2030)

10.3.3.  Market Revenue and Forecast, by Indication (2017-2030)

10.3.4.  India

10.3.4.1.      Market Revenue and Forecast, by Phase (2017-2030)

10.3.4.2.      Market Revenue and Forecast, by Study Design (2017-2030)

10.3.4.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.3.5.  China

10.3.5.1.      Market Revenue and Forecast, by Phase (2017-2030)

10.3.5.2.      Market Revenue and Forecast, by Study Design (2017-2030)

10.3.5.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.3.6.  Japan

10.3.6.1.      Market Revenue and Forecast, by Phase (2017-2030)

10.3.6.2.      Market Revenue and Forecast, by Study Design (2017-2030)

10.3.6.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.3.7.  Rest of APAC

10.3.7.1.      Market Revenue and Forecast, by Phase (2017-2030)

10.3.7.2.      Market Revenue and Forecast, by Study Design (2017-2030)

10.3.7.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.4.        MEA

10.4.1.  Market Revenue and Forecast, by Phase (2017-2030)

10.4.2.  Market Revenue and Forecast, by Study Design (2017-2030)

10.4.3.  Market Revenue and Forecast, by Indication (2017-2030)

10.4.4.  GCC

10.4.4.1.      Market Revenue and Forecast, by Phase (2017-2030)

10.4.4.2.      Market Revenue and Forecast, by Study Design (2017-2030)

10.4.4.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.4.5.  North Africa

10.4.5.1.      Market Revenue and Forecast, by Phase (2017-2030)

10.4.5.2.      Market Revenue and Forecast, by Study Design (2017-2030)

10.4.5.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.4.6.  South Africa

10.4.6.1.      Market Revenue and Forecast, by Phase (2017-2030)

10.4.6.2.      Market Revenue and Forecast, by Study Design (2017-2030)

10.4.6.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.4.7.  Rest of MEA

10.4.7.1.      Market Revenue and Forecast, by Phase (2017-2030)

10.4.7.2.      Market Revenue and Forecast, by Study Design (2017-2030)

10.4.7.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.5.        Latin America

10.5.1.  Market Revenue and Forecast, by Phase (2017-2030)

10.5.2.  Market Revenue and Forecast, by Study Design (2017-2030)

10.5.3.  Market Revenue and Forecast, by Indication (2017-2030)

10.5.4.  Brazil

10.5.4.1.      Market Revenue and Forecast, by Phase (2017-2030)

10.5.4.2.      Market Revenue and Forecast, by Study Design (2017-2030)

10.5.4.3.      Market Revenue and Forecast, by Indication (2017-2030)

10.5.5.  Rest of LATAM

10.5.5.1.      Market Revenue and Forecast, by Phase (2017-2030)

10.5.5.2.      Market Revenue and Forecast, by Study Design (2017-2030)

10.5.5.3.      Market Revenue and Forecast, by Indication (2017-2030)

Chapter 11.  Company Profiles

11.1.              Novartis

11.1.1.  Company Overview

11.1.2.  Product Offerings

11.1.3.  Financial Performance

11.1.4.  Recent Initiatives

11.2.              Covance

11.2.1.  Company Overview

11.2.2.  Product Offerings

11.2.3.  Financial Performance

11.2.4.  Recent Initiatives

11.3.              Medpace

11.3.1.  Company Overview

11.3.2.  Product Offerings

11.3.3.  Financial Performance

11.3.4.  Recent Initiatives

11.4.              Charles River Laboratories

11.4.1.  Company Overview

11.4.2.  Product Offerings

11.4.3.  Financial Performance

11.4.4.  Recent Initiatives

11.5.              Syneous Health

11.5.1.  Company Overview

11.5.2.  Product Offerings

11.5.3.  Financial Performance

11.5.4.  Recent Initiatives

11.6.              Icon Plc

11.6.1.  Company Overview

11.6.2.  Product Offerings

11.6.3.  Financial Performance

11.6.4.  Recent Initiatives

11.7.              GlaxoSmithKline

11.7.1.  Company Overview

11.7.2.  Product Offerings

11.7.3.  Financial Performance

11.7.4.  Recent Initiatives

11.8.              Aurora healthcare

11.8.1.  Company Overview

11.8.2.  Product Offerings

11.8.3.  Financial Performance

11.8.4.  Recent Initiatives

11.9.              Biogen

11.9.1.  Company Overview

11.9.2.  Product Offerings

11.9.3.  Financial Performance

11.9.4.  Recent Initiatives

11.10.           IQVIA

11.10.1.               Company Overview

11.10.2.               Product Offerings

11.10.3.               Financial Performance

11.10.4.               Recent Initiatives

Chapter 12.  Research Methodology

12.1.              Primary Research

12.2.              Secondary Research

12.3.              Assumptions

Chapter 13.  Appendix

13.1.              About Us

13.2.              Glossary of Terms

Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/38683

Contact Us:

Vision Research Reports

Call: +1 9197 992 333

Email: sales@visionresearchreports.com

Show More

Related Articles

Back to top button